Oncology Central

Immunotherapy nivolumab given the green light by NICE for non-small cell lung cancers

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending the breakthrough immunotherapy, nivolumab, for use in non-small cell lung cancer patients (NSCLC) in England.

The recommendation from NICE will make nivolumab available immediately, via the Cancer Drugs Fund (CDF). Nivolumab will be reimbursed, after chemotherapy, for all patients with locally advanced or metastatic squamous NSCLC and in non-squamous NSCLC patients whose tumours are PD-L1 positive.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.